Conference Coverage
NewsNetwork
OncLive TV
PEER EXCHANGE
OncLive INSIGHTS
VISITING CHICAGO? JOIN US IN RECOGNIZING OUR 2018 GIANTS OF CANCER CARE® ON MAY 31st AND VISIT BOOTH 2073 JUNE 2nd-4th!
SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Neoadjuvant HER2+
More >>
<< View More Conferences

2017 World Congress on GI Cancer

Oncology Conference Multimedia
View more videos >>
Dr. Modest on Study of Surgical Intervention in CRC
Dr. Modest on Study of Surgical Intervention in CRC
Dr. Ott on the CheckMate-032 Study in Gastric and GEJ Cancer
Dr. Ott on the CheckMate-032 Study in Gastric and GEJ Cancer
Dr. Argiles on Study of Carcinoembryonic Antigen T-Cell Bispecific Antibody
Dr. Argiles on Study of Carcinoembryonic Antigen T-Cell Bispecific Antibody
Oncology Conference Articles
Biomarker Analysis Identifies Prognostic Markers for Aflibercept Efficacy in CRC
Biomarker Analysis Identifies Prognostic Markers for Aflibercept Efficacy in CRC
Ziv-aflibercept (Zaltrap) prolonged overall survival compared to placebo across subgroups of patients with metastatic colorectal cancer with wild-type and mutated RAS, KRAS, and BRAF genes.
CRC Patients With Liver Metastasis Receive Unanticipated Benefit From SIRT
CRC Patients With Liver Metastasis Receive Unanticipated Benefit From SIRT
While expected improvements in survival did not emerge with SIRT plus chemotherapy, an unanticipated benefit was observed with SIRT in patients with metastatic colorectal cancer. 
Expert Discusses Surgical Intervention in Metastatic CRC
Expert Discusses Surgical Intervention in Metastatic CRC
In a central evaluation for surgical treatment options in the FIRE-3 study results, investigators set out to determine the number of patients with metastatic colorectal cancer who had resectable disease during systemic first-line therapy.
Napabucasin Clinically Active in Both Pancreatic and Colon Cancer
Napabucasin Clinically Active in Both Pancreatic and Colon Cancer
The novel stemness inhibitor napabucasin in combination with different standard chemotherapy backbones demonstrated promising activity in metastatic pancreatic adenocarcinoma and metastatic colorectal cancer.
Novel Bispecific Antibody Effective for Heavily Pretreated mCRC
Novel Bispecific Antibody Effective for Heavily Pretreated mCRC
CEA-TCB showed a favorable safety profile and promising efficacy in patients with heavily-pretreated microsatellite stable metastatic colorectal cancer, with enhanced efficacy when combined with atezolizumab.
Liquid Biopsies Identify Mechanisms of Resistance in Gastrointestinal Cancers
Liquid Biopsies Identify Mechanisms of Resistance in Gastrointestinal Cancers
Aparna Parikh, MD, discusses the potential impact of liquid biopsies in overcoming resistance to targeted therapies in gastrointestinal cancer.
Occurrence of Hand-Foot Skin Response May Signal Regorafenib Activity in Hepatocellular Carcinoma
Occurrence of Hand-Foot Skin Response May Signal Regorafenib Activity in Hepatocellular Carcinoma
Patients with unresectable HCC continue to show statistically significant improvement in overall survival with second-line regorafenib (Stivarga) treatment.
Advanced Age Presents No Barrier to Successful Nivolumab Treatment in HCC
Advanced Age Presents No Barrier to Successful Nivolumab Treatment in HCC
Durable responses and improved long-term survival were demonstrated with nivolumab (Opdivo) that were not altered by the age of patients with advanced hepatocellular carcinoma across all age groups of patients participating in the CheckMate 040 trial.
Expert Discusses Tumor Location and Mutational Status in CRC
Expert Discusses Tumor Location and Mutational Status in CRC
Julien Taieb, MD, discusses the prognostic value of primary tumor location in colon cancer.
HA Levels Predict PEGPH20 Response in Metastatic Pancreatic Cancer
HA Levels Predict PEGPH20 Response in Metastatic Pancreatic Cancer
The addition of pegvorhyaluronidase alfa (PEGPH20) to standard nab-paclitaxel/gemcitabine improved progression-free survival over standard therapy in patients with metastatic pancreatic ductal adenocarcinoma.
AM0010 Plus FOLFOX Shows Promise in Metastatic Pancreatic Cancer
AM0010 Plus FOLFOX Shows Promise in Metastatic Pancreatic Cancer
Combination therapy with AM0010, a PEGylated human interleukein (IL)-10, plus fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) demonstrated encouraging clinical activity in metastatic pancreatic ductal adenocarcinoma. 
Publications
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
Publication Bottom Border
Border Publication
 
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-939-0221

Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.
 
x